We report here for the ®rst time, that the SV40 small tantigen inhibits mammary gland dierentiation during mid-pregnancy and that about 10% of multiparous WAP-SVt transgenic animals develop breast tumors with latencies ranging from 10 ± 17 months. Cyclin D1 is deregulated and over expressed in the small t-antigen positive mammary gland epithelial cells (ME-cells) and in the breast tumor cells. SV40 small t-antigen immortalized ME-cells (t-ME-cells) exhibit a strong intranuclear cyclin D1 staining, also in the absence of external growth factors and the cells continue to divide for several days without serum. In addition, the expression rate of cyclin E and p21
Introduction
Mammary gland dierentiation requires a complex interplay of various tissue and lactotrophic hormones (e.g. estrogen, progesterone, prolactin, insulin, hydrocortisone) as well as cell ± cell and cell ± matrix interactions. During the early stage of pregnancy adipose cells are the dominant cell type, with the majority of them being replaced by epithelial cells (ME-cells) during late pregnancy (days 18 ± 19). Ductal branching and alveolar development are stimulated by progesterone and synthesis of the progesterone receptor is induced by estrogen. Lactogenesis and milk secretion requires the synergistic action of prolactin and glucocorticoids (Wang et al., 1990; Senkiti and Banerjee, 1979; Santarelli et al., 1996) . After lactation, the majority of the ME-cells are eliminated by apoptosis and replaced by the adipose cells (Tzeng et al., 1998) but the signals regulating the cell death program are still not well understood.
To study the molecular biology of mammary gland dierentiation and breast cancer formation in greater details, various transgenic lines were established, which overexpress either key regulators of the cell cycle or tumor genes that disturb the balance between cell dierentiation and/or the cell death program such as the SV40 T/t-antigens (Tzeng et al., 1993; Li et al., 2000; Schulze-Garg et al., 2000; Siegel et al., 2000) . Although there is no indication that the SV40 virus is involved in human breast cancer formation, the T/tantigens are useful tools to study mammary gland dierentiation and tumorigenesis. Both viral proteins mimic alterations etiologically linked with human breast cancer. Among other functions, the large Tantigen binds and functionally inactivates the p53 and pRb tumor suppressor proteins (reviewed in May and May, 1999; DeCaprio, 1999) and the small t-antigen associates and inhibits the serine/threonine phosphatase PP2A (Rundell, 1987; Scheidtmann et al., 1982; Mumby and Walter, 1991) .
We recently established transgenic lines which carry the early SV40 coding region under the transcriptional control of the whey acidic milk protein promoter (WAP-SVT/t). Transcription of the WAP-SVT/t transgene occurs exclusively in the ME-cells of the mammary glands in synchrony with the endogenous WAP gene (Tzeng et al., 1993) . Animals of these lines exhibit an almost regular mammary gland development until the late pregnancy (days 18 ± 19), but before parturition the majority of the ME-cells are eliminated by apoptosis and the females can not feed their litters . The T/t-antigens induced p53 independent apoptosis continues also in T/t-antigen positive ME-cells of established tissue culture lines (Tzeng et al., 1998) . Our studies revealed further, that the T/t-antigens sensitize the ME-cells to oxydative stress, which leads to apoptosis. Treatment of the T/tantigen positive ME-cells with catalase, a scavenger of H 2 O 2 inhibits apoptosis. Moreover, low amounts of H 2 O 2 increases the apoptosis rate of T/t-antigen positive ME-cells whilst T/t-antigen negative ME-cells are signi®cantly more resistant to H 2 O 2 treatment (Kohlho et al., 2000) .
Furthermore, all WAP-SVT/t females develop breast cancer after the ®rst lactation period. Tumor formation occurs mostly in the inguinal or axillary glands after a six-month latency period. Although breast cancer is mortal for all transgenic females and for about 30% of the WAP-SVT/t males , the transformation rate relative to the number of cells is low, considering the fact that a large number of T/tantigen positive ME-cells remain in mammary glands after lactation and that tumor formation occurs mainly in a clonal fashion in particular glands after a long latency period. Likewise, only a small fraction of T/tantigen positive ME-cells acquire anchorage-independent growth in tissue culture (personal observation). These observations indicate that T/t-antigen synthesis per se is not sucient to cause malignant ME-cell transformation and that further genetic alterations are required for tumor progression.
To distinguish between the small t-antigen and the large T-antigen functions involved in deregulation of the mammary gland development and that are critical for breast cancer formation, we generated transgenic lines in which animals synthesize either the small tantigen (WAP-SVt) or the large T-antigen (WAP-SVT). Animals of two WAP-SVt lines express the WAP-SVt transgene with a high rate (WAP-SVt/1, WAP-SVt/6) and animals of one line (WAP-SVt/8) with a low eciency. Signi®cantly, high small tantigen levels induce constitutive expression of cyclin D1 and a premature ME-cell multiplication. This prevents mammary gland dierentiation and inhibits milk protein synthesis but the small t-antigen does not induce ME-cell apoptosis. In agreement with the hypothesis that overexpression of cyclin D1 promotes tumor progression (Wang et al., 1994) , we observed that about 10% of the WAP-SVt/1 and WAP-SVt/6 animals developed breast cancer. In contrast, the WAP-SVt/8 animals exhibit a normal mammary gland development and breast cancer formation was not observed.
The large T-antigen positive animals exhibit an almost normal mammary gland development until late pregnancy but shortly after parturition the majority of the ME-cells are eliminated by apoptosis, which limits the lactation capability of these animals. When compared with the WAP-SVT/t animals, the tumor rate of the WAP-SVT animals is lower and the latency period is increased, indicating that the high breast tumor rate is a synergistic eect of the T/t-antigens.
The last category of transgenic animals presented here carries the WAP-SVBst-Bam transgene. The SV40 Bst-Bam DNA segment encodes only for the second exon of the large T-antigen and animals of these lines synthesize two truncated T-antigen molecules, the T1-antigen and the T2-antigen. As described elsewhere (Eul et al., 1995) , the T1-antigen is generated by homologous trans-splicing and sequesters the p53 and pRb with an eciency comparable to that of the large T-antigen. The T2-antigen lacks the LXCXE pRbbinding domain and thus sequesters only p53 (Eul et al., 1995) . Animals of all WAP-SVBst-Bam lines (eight) exhibit a normal mammary gland development and feeding capability and the animals do not develop breast cancer.
SV40 small t-antigen ± but not the large T-antigen ± prevents mammary gland dierentiation during pregnancy
To test whether SV40 small t-antigen aects mammary gland development, three independent transgenic lines were generated (WAP-SVt/1, WAP-SVt/6, WAP-SVt/ 8). To permit only small t-antigen synthesis, the large T-antigen 5' splice site on the WAP-SVT/t DNA was modi®ed by site directed mutagenesis as is illustrated in Figure 1 (CTGAG/GTATTT to CTGAA/GTCTT). This alteration entirely prevents large T-antigen mRNA splicing but does not change the amino acid sequence of the small t-antigen. Commencement of small t-antigen synthesis occurs in the mammary gland epithelial cells (ME-cells) during the ®rst pregnancy, as is demonstrable by RT ± PCR (Figure 2a ) and Western blot analysis ( Figure 2b ) and continues after the lactation period in the remaining ME-cells. Animals of the three lines express the WAP-SVt transgene with a dierent eciency, with it being high in the ME-cells of the WAP-SVt/1 and WAP-SVt/6 animals but low in the ME-cells of the WAP-SVt/8 animals (Figure 2a, b) . As expected, large T-antigen synthesis was demonstrable neither by Western blot nor by RT ± PCR analysis in the ME-cells of all three WAP-SVt lines (Figure 2a, b) .
One characteristic of the WAP-SVt/1 and WAP-SVt/ 6 females is the inability to feed their litters, whereas animals of the WAP-SVt/8 line have a normal feeding capability and foster mothers are not required for nursing. The`milkless' phenomenon of the WAP-SVt/1 and WAP-SVt/6 animals is due to an under development of the mammary glands during early pregnancy. In the mammary glands of normal (strain: NMRI) and WAP-SVt/8 animals, the majority of the adipose cells are replaced by the ME-cells during late pregnancy, and ME-cells are the dominant cell type during the lactation period (Figure 3a,b) . In contrast, in the females of the WAP-SVt/1 and WAP-SVt/6 lines the small t-antigen triggers early ME-cell proliferation but inhibits the development of the alveolar and ductal t-antigen inhibits mammary gland differentiation F Goetz et al network speci®c for normal mammary glands, and the adipose cells still occupy a signi®cant part of the mammary gland during late pregnancy and the lactation period (Figure 3c ,d). The milk production is very low and WAP-gene expression is demonstrable by RT ± PCR analysis ( Figure 4a ) but not by Western blotting (Figure 4b ).
To explore whether the large T-antigen also inhibits mammary gland development, three independent transgenic lines were generated. These animals synthesize only the SV40 large T-antigen in the ME-cells (WAP-SVT/12, WAP-SVT/14, WAP-SVT/17). The WAP-SVT transgene has a mutated 5' splice site consensus sequence (Figure 1 : AAG/GTAAAT to Figure 1 Schematic presentation of the WAP-T-antigen DNA constructs. WAP-SVT/t: The transgene contains the entire early SV40 coding region with the WAP-promoter. The dark bars represent the two T-antigen exons and the t-antigen. The 5' splice site sequences of both T/t-antigens are shown. WAP-SVT: In this construct, the t-antigen 5' splice sequence was changed by site directed mutagenesis (AAG/GTAATT to AAG/CGCAAT). This mutation entirely inhibits t-antigen synthesis, indicated as open bar. The amino acids of the two T-antigen exons are shown (aa 1 ± 82 ®rst exon; aa 83 ± 708 second exon). WAP-SVt: The T-antigen 5'-splice site was inactivated by site directed mutagenesis (CTGAG/GTATTT to CTGAA/GTCTTT). The open bars indicate inhibition of Tantigen synthesis. WAP-SVBst-Bam: The WAP promoter was linked to the SV40 Bst-Bam DNA fragment which contains only the coding sequence for the second T-antigen exon and the intact T/t-antigens 3' splice site; the t-antigen 5' splice site is mutated as illustrated in the WAP-SVT DNA construct. The nucleotide sequence encoding for the T-antigen amino acids 132 ± 133 represents a cryptic 5' splice site. T2: Schematic description of the T2-antigen with the amino acid sequence 109 ± 708. The T-antigen codon 109 is the ®rst AUG in the reading frame of the second T-antigen exon. The p53 binding region is indicated. T1: The T1-antigen contains two exons. The ®rst exon corresponds to the T-antigen amino acids sequence 109 ± 132 and the second exon to the amino acid sequence 83 ± 708. As described elsewhere (Eul et al., 1995) , the T1-antigen mRNA is generated by homologous trans-splicing. The pRB and the p53 binding sites are indicated Oncogene t-antigen inhibits mammary gland differentiation F Goetz et al AAG/CGCAAT), thus preventing small t-antigen mRNA splicing. Animals of all three lines exhibit an almost normal mammary gland development but at late pregnancy the large T-antigen triggers both MEcell proliferation and apoptosis (Figure 3e,f) . However, the balance between these two large T-antigen functions is not maintained during the lactation period, causing a continuous loss of ME-cells and hence a strong decline in milk protein synthesis during the ®rst days of lactation.
So far it is uncertain which of the multiple small tantigen functions inhibits mammary gland dierentiation, but we have reasons to speculate that this is triggered by association of the small t-antigen with the serine/threonine protein phosphatase (PP2A). Inhibition of the PP2A phosphatase causes not only a prolonged activation of the mitogen activated protein (MAP) kinase pathway but under certain conditions also aects both cell dierentiation and the cell death program (reviewed in Mumby and Walter, 1993; Sontag et al., 1997; Garcia et al., 2000; Virshup, 2000) . It is well established that small t-antigen mediates the cell cycle progression (Cicala et al., 1994 ), but we did not observe that small t-antigen induces ME-cell apoptosis in the mammary glands or in established tissue culture cell lines generated from the small t-antigen breast tumors (t-ME-cells). On the contrary, the t-ME-cells are resistant to serum depletion and continue to divide for several days in medium without serum. However, the immortalized t-ME-cells are sensitive to H 2 O 2 treatment, which mainly induces ME-cell necrosis but not apoptosis (Graessmann et al., in preparation for publication). We also established dierent immortalized large Tantigen-positive ME-cell lines (T-ME-cells) and found that both serum depletion and H 2 O 2 treatment mainly cause apoptosis but not necrosis (Graessmann et al., in preparation for publication). It is worthwhile to Mammary gland tissue segments were isolated from the transgenic animals at day 18 of pregnancy and from breast tumors. RNA was isolated using TRIZOL (Life Technologies Inc.) and DNase treated RNA was converted into cDNA and PCR ampli®ed (25, 30, 35 cycles), utilizing the SV40 T/t-antigen speci®c primer pair 5'-GCTTTGCAAAGATGGATAAAG-3' and 5'-ACTAAACA-CAGCATGACTC-3'. The predicted length of the PCR product is 737 bp for the small t-antigen and 457 bp for the large Tantigen. The PCR products were separated on 1.5% agarose gels (S-M: size marker; T/t M: RT ± PCR product obtained from WAP-SVT/t positive ME-cells). (b) Western blot analysis. Cell lysates were prepared from mammary gland and breast tumor segments (lysis buer: 50 mM Tris-HCl, pH 7.8, 150 mM NaCl, 2.5 mM EDTA, 1% NP-40, 1 mM PMSF and 1 mg/ml of the protease inhibitors Pepstatin, Aprotinin and Leupeptin). Protein extracts (500 mg) were treated with a monoclonal mouse antibody TAg(Ab-1) (Oncogene) which recognizes both T/t-antigens and with Protein A (Pierce). The immunoprecipitates were separated on 12% and 7.5% SDS ± polyacrylamide gels, electroblotted onto PVDF membrane (Roth) and probed with TAg(Ab-1) antibody. The blot was developed with the chemiluminescence detection system (NEN) Figure 3 Mammary gland histology. Sections were obtained from normal animals (a, b) and from transgenic animals: WASVt/ 1 (c, d); WAP-SVT/12 (e, f). Tissue segments were isolated at day 18 of pregnancy (a, c, e) and at the ®rst day of the lactation period (b, d, f). WAP-SVt/1 tumor section (g). Haemalaun-Eosin stained sections; original magni®cation 2506 t-antigen inhibits mammary gland differentiation F Goetz et al mention that both the large T-antigen and the small tantigen mediate immortalization of the ME-cells under standard tissue culture conditions (DMEM, 10% FCS) with a high eciency, while ME-cells from normal mice exhibit a very short life-span in tissue culture (Goetz et al., in preparation for publication). The above observations led us to the working hypothesis that high levels of small t-antigen cause premature ME-cell division during early pregnancy in the absence of external mitotic signals that are required for normal mammary gland development Santarelli et al., 1996) . These MEcells are not fully dierentiated and do not respond to the dierentiation signals at late pregnancy, thus the WAP levels remain permanently low (e.g. WAP-SVt/1; Figure 4 ). Since p53 and pRb tumor suppressor proteins are known to be key regulators of both the cell cycle and of apoptosis, we further tested whether sequestration of these proteins by the large T-antigen is sucient to induce ME-cell apoptosis during pregnancy. To this end, eight independent transgenic lines were generated which carry and express the WAP-SVBstBam transgene in the ME-cells. As shown in Figure  1 , the WAP-SVBst-Bam DNA construct encodes for the second T-antigen exon and contains the T/tantigens 3' splice site. Animals of the WAP-SVBstBam lines (e.g. WAP-SVBst-Bam/8) synthesize two truncated T-antigen molecules in the ME-cells, the T1-and the T2-antigens (Figures 1 and 5a) . The T2-antigen contains the T-antigen amino acid sequence 109 ± 708 (codon 109 is the ®rst AUG at the second T-antigen exon) and sequesters the p53 (Eul et al., 1995) . The T1-antigen consists of two exons; one exon contains the large T-antigen amino acid sequence (aa) 109 ± 132 and the other exon the aa 83 ± 708. As we have demonstrated elsewhere, the T1-antigen mRNA is generated by homologous transsplicing and the cells utilize two identical pre-mRNA molecules to generate one intact T1-mRNA molecule (Eul et al., 1995) . Since the T1-antigen contains the LXCXE domain (aa 103 ± 107) it also sequesters the pRb with a similar eciency to that of the wt large T-antigen (Figure 5b ). Long-term analysis has revealed that the T1/T2-antigens aect neither mammary gland dierentiation nor the lactation capability of the WAP-SVBst-Bam animals. ME-cell apoptosis occurs only after weaning but not during pregnancy or the lactation period. Signi®cantly, mammary gland dierentiation and milk production are blocked in double-transgenic WAP-SVt/1´WAP-SVBst-Bam/8 animals (data not shown), indicating that the T1/T2-antigens can not overcome the inhibitory activity of the small t-antigen. 
SV40 small t-antigen induces breast cancer formation at a low frequency
It is well established that small t-antigen is required for ecient transformation of various cell types, especially when cells are in growth arrest (Martin et al., 1979) . Since small t-antigen synthesis continues in the MEcells remaining in the mammary glands after weaning, we asked whether this has a long-term eect on the animals. Therefore, multiparous (2 ± 3 pregnancies) females from all three WAP-SVt lines were monitored for an 18-month period after the ®rst pregnancy period. As summarized in Table 1 , 12% (5/41) of the WAP-SVt/1 and 6% (2/32) of the WAP-SVt/6 animals developed t-antigen-positive breast tumors (Figure 3g) . Formation of the adenocarcinomas occurred with latencies ranging from 10 to 17 months, mostly as single tumors in inguinal or axillary glands. Animals of the WAP-SVt/8 line did not develop breast tumors (0/60).
It is well established that p53 alterations are frequently associated with cancer formation (May and May, 1999) , and p53 mutations (e.g. aa 242 Gly/ Ala) have also been observed in WAP-SVT/t tumor cells (Tzeng et al., 1998) . In contrast, p53 mutations were not detectable in the ME-cells of any t-antigen tumor (data not shown). We further investigated whether p53 and pRb inactivation by the large Tantigen is sucient to induce breast cancer formation, monitoring multiparous females of all eight WAPSVBst-Bam transgenic lines over a 20-month period. However, none of these animals (0/4150) developed breast cancer. Therefore, sequestration of the p53 and pRb by the T-antigen is not sucient to cause breast cancer formation in mice. In this regard, it is of interest to mention also that we did not observe breast cancer formation in p53 7/7 animals ( Table 1) .
SV40 small t-antigen deregulates Cyclin D1
Progression of the cells through the G 1 phase of the cell cycle depends upon cyclin D/CDK4 and cyclin E/ CDK2 activities. Mitotic signals induce cyclin D expression, which reaches a maximal level at the mid-G 1 phase, forming the functional protein kinase complex with either CDK4 or CDK6. Hyperphosphorylation of pRb by cyclin D/CDK4 leads to activation of the E2F transcription factor and to cyclin E gene expression. The cyclin E/CDK2 complex traverses the cells into the S phase. Deregulation of the G1 cyclins was observed in human breast cancer Waf1 level and complex formation of p21 Waf1 with cyclin D1, cell lysates were prepared from t-ME-cells and T-MEcells (two independent immortalized t-ME-cell and T-ME-cell lines). Cell lysates (500 mg) were treated with polyclonal rabbit p21
Waf1 antibody (PharMingen) and Protein A. Precipitated proteins were separated on 10% SDS ± PAGE and the blot was ®rst hybridized with the p21
Waf1 antibody and after stripping hybridized with the monoclonal mouse cyclin D1 antibody (72-13G, Santa Cruz Biotechnology). (c) For detection of hyperphosphorylated pRb, t/1-ME-cell and T/12-ME-cell lysates were subjected for blot analysis utilizing the monoclonal mouse pRb antibody (G3-245, PharMingen). pRb Marker: Molt-4 cell lysate (PharMingen) t-antigen inhibits mammary gland differentiation F Goetz et al cells (Hunter and Pines, 1994) . Transgenic animals overexpressing the cyclins exhibited developmental abnormalities of the mammary gland and developed breast cancer (Wang et al., 1994) . To explore whether the small t-antigen deregulates cyclin D1 expression, mammary gland tissue segments were isolated from transgenic and control animals at late pregnancy (day 18) and the cell lysates were subjected to Western blot analysis. As shown in Figure  6a , ME-cells from WAP-SVt/1 animals contain signi®cantly higher concentrations of cyclin D1 than the ME-cells of normal, WAP-SVt/8 or of the WAP-SVT/ 12 animals. High levels of cyclin D1 are also demonstrable in the WAP-SVt/1 tumors but not in the large T-antigen-induced breast tumor cells ( Figure  6a) .
We further established ®ve independent immortalized ME-cell lines from dierent t-antigen breast tumors (t-ME-cells). Immuno¯uorescence staining revealed that the majority (90 ± 95%) of the t-ME-cells of all isolates exhibit a strong intranuclear cyclin D1 accumulation. Cyclin D1 expression is cell cycle independent and also demonstrable in the M-phase of the cell cycle (Figure 7a) . Furthermore, the cyclin D1 level remains high after serum withdrawal (Figure 7b ) and the t-ME-cells still divide eciently after a 72 h starvation period (Figure 7c,d) . In contrast, cells obtained from large T-antigen tumors (T-ME-cell lines) exhibit low cyclin D1 levels (Figure 7h ). So far it is uncertain how t-antigen causes cyclin D1 deregulation. We could not demonstrate a direct link between extracellular-signal related kinase 1 (ERK1) activity and the elevated cyclin D1 levels by either Western blot analysis (Figure 8 ) or immuno¯uorescence staining in the t-ME-cells cultivated in DME-medium with or without serum. Also addition of the MEK1 inhibitor (BioLabs, PD98059, 50 mM) to the culture medium for 4 ± 22 h did not signi®cantly reduce the cyclin D1 level and the BrdU incorporation rate. Furthermore, South- Figure 7 Immuno¯uorescence staining. (a) t-ME-cells grown under standard culture conditions (DME-medium, 10% FCS) were ®xed (methanol/acetone) and stained with cyclin D1 antibody. (b) t-ME-cells were grown for 48 h in DME-medium without serum ®xed and stained with the cyclin D1 antibody. (c) t-ME-cells were grown for 72 h in DME-medium without serum ®xed and stained with Hoechst dye. (d) The same ME-cells as shown in (c) stained with BrdU antibodies (Roche). BrdU was added to the culture medium for a 12 h labeling period, 60 h after serum withdrawal. (e) t-ME-cells stained with cyclin E antibody. (f) t-ME-cells stained with p21 WAF1 antibody. (g) t-ME-cells stained with p53 antibody. (h) T-ME-cells stained with cyclin D1 antibody Figure 8 Cyclin D1 and ERK1 Western blot analysis after serum starvation. t-ME-cells and T-ME-cells were cultivated for 24 h in DME-medium without (7) and with (+) 10% fetal calf serum. Cell extracts were prepared using RIPA-buer (50 mM Tris-HCl, pH 7.8, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate, 1 mM PMSF and 1 mg/ml of the protease inhibitors Pepstatin, Aprotinin and Leupeptin) and subjected to gel electrophoresis (10% SDS ± PAGE, 80 mg total protein). The blots were either hybridized with the monoclonal mouse cyclin D1 antibody (72-13G, Santa Cruz Biotechnology) or the monoclonal mouse b-Actin antibody (AC-74, Sigma). For detection of the active phosphorylated form of ERK (ERK1-P) 1 mg total protein of each cell extract was immunoprecipitated with ERK1 rabbit polyclonal antibody (C16, Santa Cruz Biotechnology) and Protein A (Pierce). Blot was hybridized with the ERK1 antibody Oncogene t-antigen inhibits mammary gland differentiation F Goetz et al ern blot analysis and DNA sequencing experiments exclude cyclin D1 gene-ampli®cation/DNA rearrangement or mutation as the reason for elevated cyclin D1 levels in the t-ME-cells (data not shown).
Cyclin D-and cyclin E-dependent CDK activities are counter-regulated by at least two families of inhibitors, the INK4 and the Cip1/Kip proteins (e.g. p21
Waf1
). The p21
Waf1 has a dual function with respect to the G 1 -cyclins, it facilitates cyclin D/CDK4 association and promotes nuclear accumulation of the kinase complex, while it inhibits the cyclin E/CDK2 activity (Dotto, 2000) . As shown in Figure 7f about 40 ± 60% of the t-ME-cells exhibit a strong intranuclear p21
Waf1 staining. Coimmunoprecipitation experiments revealed that the majority of the p21
Waf1 molecules are complexed with cyclin D1, as is shown for the t-ME-cells of two independent cell lines (Figure 6b ). However, cyclin E, which is also upregulated in the t-ME-cells (Figure 7e ) is not coprecipitable with p21
Waf1 (data not shown).
That p21
Waf1 does not inhibit the CDK's is further indicated by the fact that hyperphosphorylation of pRb is not prevented in the t-ME-cells (Figure 6c ). Elevated p53 levels were neither demonstrable by RT ± PCR analysis (data not shown) nor by immuno¯uorescence staining in t-ME-cells grown in medium with or without serum (Figure 7g ). This implies that p21 Waf1 up-regulation is p53 independent. Overexpression of the p21
Waf1 gene occurs also frequently in p53 negative human breast cancer cells (Wakasugi et al., 1997) .
In summary, we have demonstrated for the ®rst time that the SV40 small t-antigen inhibits mammary gland dierentiation and induces with a low rate breast cancer formation, while it immortalizes ME-cells with a high eciency. Further experiments utilizing mutated small t-antigen versions should be carried out to determine whether a single small t-antigen function (e.g. PP2A inhibition) accounts for the eects shown above or whether multiple t-antigen functions are involved.
